Phoenix Biotech Acquisition Debt to Equity

Phoenix Biotech Acquisition (PBAX) currently reports a debt-to-equity ratio of -0.28. That is below the sector sector average of 0.2. Use the charts on this page to explore Phoenix Biotech Acquisition's debt-to-equity ratio history and peer comparisons.

Phoenix Biotech Acquisition's debt-to-equity ratio of -0.28 is lower than the its sector sector average of 0.2. That is roughly 240.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Phoenix Biotech Acquisition's market price to a fundamental measure such as earnings, sales, or book value. At -0.28, PBAX can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of -0.28, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 0.2. From there, open related valuation or income-statement pages for Phoenix Biotech Acquisition, and consider following PBAX for alerts when major investors trade the stock.